12/11
08:22 am
atxs
Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE [Yahoo! Finance]
Medium
Report
Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE [Yahoo! Finance]
12/11
08:00 am
atxs
Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE
Medium
Report
Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE
12/10
12:21 pm
atxs
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Low
Report
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
12/10
08:20 am
atxs
Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis [Yahoo! Finance]
Medium
Report
Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis [Yahoo! Finance]
12/10
08:00 am
atxs
Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis
Low
Report
Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis
12/3
04:10 pm
atxs
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/14
01:34 pm
atxs
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Medium
Report
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
11/14
08:23 am
atxs
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its price target raised by analysts at Oppenheimer Holdings Inc. from $26.00 to $28.00. They now have an "outperform" rating on the stock.
Medium
Report
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its price target raised by analysts at Oppenheimer Holdings Inc. from $26.00 to $28.00. They now have an "outperform" rating on the stock.
11/13
04:22 pm
atxs
Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update [Yahoo! Finance]
Medium
Report
Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update [Yahoo! Finance]
11/13
04:10 pm
atxs
Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
Medium
Report
Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
11/13
08:00 am
atxs
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference
Medium
Report
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference
11/4
04:10 pm
atxs
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/2
09:03 pm
atxs
Ypsomed Holding (SWX:YPSN) Partners with Astria for STAR-0215 Autoinjector Amid Valuation Concerns [Yahoo! Finance]
Low
Report
Ypsomed Holding (SWX:YPSN) Partners with Astria for STAR-0215 Autoinjector Amid Valuation Concerns [Yahoo! Finance]
10/30
08:00 am
atxs
Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting
Low
Report
Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting
10/21
08:00 am
atxs
Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
Low
Report
Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
10/18
09:07 am
atxs
Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth [Yahoo! Finance]
Medium
Report
Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth [Yahoo! Finance]
10/16
08:00 am
atxs
European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics’ Investigational Therapy for the Treatment of Hereditary Angioedema
Low
Report
European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics’ Investigational Therapy for the Treatment of Hereditary Angioedema